Harmony Biosciences Holdings, Inc. (HRMY) Stock Forecast
HRMY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 11 analysts
- Price target
- $48.25 average of analyst targets
- Upside to target
- +27.1% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $1.03
- 52-week range
- $26.02 – $42.86
HRMY analyst ratings
11 analystsNumber of analysts at each rating.
HRMY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HRMY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.47 | $1.41 | $1.53 | $1.08 | +35.9% | 2 |
| Current fiscal year (2026) | $5.22 | $5.13 | $5.31 | $3.60 | +45.1% | 2 |
| Next fiscal year (2027) | $7.00 | $6.98 | $7.03 | $5.22 | +34.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HRMY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $274.3M | $269.7M | $278.9M | +14.5% | 12 |
| Current fiscal year (2026) | $1.03B | $1.00B | $1.04B | +18.6% | 12 |
| Next fiscal year (2027) | $1.17B | $1.07B | $1.27B | +13.2% | 12 |
HRMY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HRMY revenue: reported and forecast
HRMY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.22 | $1.22 | $1.47 | $1.47 | $1.47 | +19.9% | 3 up · 0 down |
| Current fiscal year (2026) | $4.50 | $4.55 | $5.22 | $5.22 | $5.22 | +16.1% | 2 up · 1 down |
| Next fiscal year (2027) | $6.02 | $6.02 | $6.69 | $6.69 | $7.00 | +16.4% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HRMY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HRMY beat in 7 of 12.
What analysts expect from HRMY
11 analysts cover Harmony Biosciences; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $48.25, 27.1% above the latest close of $37.95. Analysts expect earnings of $5.22 per share for 2026, +45.1% from a year earlier. For 2027 the average estimate is $7.00 per share on revenue of $1.2 billion. Harmony Biosciences beat the EPS estimate in 7 of the last 12 quarters.
Related: HRMY income statement, HRMY key metrics, HRMY chart. See the HRMY stock overview for the latest quote and news.
HRMY forecast FAQ
What is Harmony Biosciences's price target?
The average analyst price target for Harmony Biosciences is $48.25, 27.1% above the latest close of $37.95.
Is Harmony Biosciences a buy, hold or sell?
Of 11 analysts covering Harmony Biosciences, 5 rate it a strong buy, 2 a buy, 3 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Harmony Biosciences's EPS forecast?
Analysts forecast $5.22 per share for 2026 (range $5.13 to $5.31); for 2027 the estimate is $7.00.
What is Harmony Biosciences's revenue forecast?
The average revenue estimate for 2026 is $1.0 billion, growth of 18.6%; for 2027 it is $1.2 billion.
When does Harmony Biosciences report earnings?
Harmony Biosciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $1.03.
Does Harmony Biosciences usually beat earnings estimates?
Harmony Biosciences reported EPS at or above the analyst estimate in 7 of the last 12 quarters.